Natera, Inc. - Common Stock (NQ:NTRA)

416.46 +6.11 (+1.49%)

Delayed Quote Updated: 1:18 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Natera Acquires Reproductive Health Assets from Invitae

January 22, 2024

From Natera, Inc.

Via Business Wire

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

January 18, 2024

From Natera, Inc.

Via Business Wire

Expert Ratings For Natera ↗

January 17, 2024

Via Benzinga

Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle ↗

January 17, 2024

The company must pay $57 million in damages, but that's far less than expected.

Via Investor's Business Daily

Topics Intellectual Property

Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning

January 09, 2024

Via Investor Brand Network

The Analyst Landscape: 8 Takes On Natera ↗

December 29, 2023

Via Benzinga

The Latest Analyst Ratings for Natera ↗

December 12, 2023

Via Benzinga

Analyst Expectations for Natera's Future ↗

November 09, 2023

Via Benzinga

Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket ↗

January 17, 2024

Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market...

Via Benzinga

Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

January 17, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as...

Via Benzinga

Topics Stocks

Natera Provides Update on Ravgen Trial

January 16, 2024

From Natera, Inc.

Via Business Wire

Bull of the Day - NeoGenomics ↗

January 12, 2024

But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context.

Via Talk Markets

Topics Intellectual Property

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

January 09, 2024

From Natera, Inc.

Via Business Wire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

December 29, 2023

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Via Benzinga

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 29, 2023

From Natera, Inc.

Via Business Wire

US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit ↗

December 28, 2023

Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from

Via Benzinga

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

December 27, 2023

From Natera, Inc.

Via Business Wire

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 26, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

December 21, 2023

From Natera, Inc.

Via Business Wire

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

December 11, 2023

From Natera, Inc.

Via Business Wire

Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

December 06, 2023

From Natera, Inc.

Via Business Wire

Top 5 Health Care Stocks That May Collapse In November ↗

November 17, 2023

As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Natera Announces Real-World Data Collaboration with Merck

November 14, 2023

From Natera, Inc.

Via Business Wire

Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗

November 09, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Natera Reports Third Quarter 2023 Financial Results

November 08, 2023

From Natera, Inc.

Via Business Wire

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

November 08, 2023

From Natera, Inc.

Via Business Wire

Natera to Participate in November Investor Conferences

November 07, 2023

From Natera, Inc.

Via Business Wire

NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA

November 03, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

November 02, 2023

From Natera, Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.